Περίληψη:
Novel therapeutic agents targeting the epidermal growth factor receptor
(EGFR) have improved outcomes for patients with colorectal carcinoma.
However, these therapies are effective only in a subset of patients.
Activating mutations in the KRAS gene are found in 30-40% of colorectal
tumors and are associated with poor response to anti-EGFR therapies.
Thus, KRAS mutation status can predict which patient may or may not
benefit from anti-EGFR therapy. Although many diagnostic tools have been
developed for KRAS mutation analysis, validated methods and standardized
testing procedures are lacking. This poses a challenge for the optimal
use of anti-EGFR therapies in the management of colorectal carcinoma.
Here we review the molecular basis of EGFR-targeted therapies and the
resistance to treatment conferred by KRAS mutations. We also present
guideline recommendations and a proposal for a European quality
assurance program to help ensure accuracy and proficiency in KRAS
mutation testing across the European Union.
Συγγραφείς:
van Krieken, J. H. J. M.
Jung, A.
Kirchner, T.
Carneiro, F.
and Seruca, R.
Bosman, F. T.
Quirke, P.
Flejou, J. F. and
Hansen, T. Plato
de Hertogh, G.
Jares, P.
Langner, C. and
Hoefler, G.
Ligtenberg, M.
Tiniakos, D.
Tejpar, S. and
Bevilacqua, G.
Ensari, A.
